0.5 tirzepatide Eli Lilly sues companies selling alternative versions of its weight loss drug Tirzepatide | The Epoch Times

Survodutide: still in clinical trials Survodutide has no FDA approval for any indication

Many patients exploring peptide therapy are interested in maintaining energy levels, cognitive performance, recovery capacity, and overall vitality as they age

However, there is a myriad of GLP-1 receptor agonists on the market, each with its own properties and dosing regimens

GLP-1 receptors are found in several brain regions, including: The ventral tegmental area (VTA) The nucleus accumbens The prefrontal cortex When activated by GLP-1, these receptors appear to reduce the release of dopamine in response to addictive substances

Allure Medical may offer convenient home delivery options